Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

9.350 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
59 60 Next >
Novavax Stock Is Now Speculative, But it Still Has a Shot
NVAX stock has become speculative, but it still has multiple ways to win. The company needs to step up its marketing game. 
Via InvestorPlace
Novavax Could Get Analyst Downgrades Leading Up to Earnings
Novavax recently got Nuvaxovid approved for use in Japan for both primary and booster shots. It’s done nothing for NVAX stock. 
Via InvestorPlace
7 Biggest Loser Stocks That Could Become Surprising Buys
A huge pouring of red ink can sometimes lead to extraordinary gains, though you’ve got to be aware of the risks. 
Via InvestorPlace
Why Novavax Shares Are Rising
Shares of vaccine companies, including Novavax, Inc. (NASDAQ: NVAX), are trading higher amid COVID-19 concerns due to rising cases in China. 
Via Benzinga
Biotechnology Stock Novavax Enters the Buying Area
Even though Novavax's engagement in vaccine development is of high public attention, the stock price is in a decline. Right now, we see the stock price entering an inflection area. Here, we present our... 
Via Talk Markets
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Novavax Starts Dosing In COVID-19 Booster Trial In Participants Aged 12 - 17 Years
Via Benzinga
Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study
Via Benzinga
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. 
Via InvestorPlace
World's Largest Vaccine Manufacturer Stops Making COVID-19 Vaccines As 200M Doses Pile-Up: Bloomberg
Serum Institute of India Ltd, the world’s largest vaccine manufacturer, has stopped making new batches of COVID-19 shots after its stockpile grew to 200 million doses amid a global supply glut, 
Via Benzinga
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
Via Benzinga
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials. 
Via InvestorPlace
Is Novavax a Buy After Its Vaccine Approval in Switzerland?
Novavax is late to the Covid-19 vaccine race and is up against some stiff competition. NVAX stock is in a tough spot. 
Via InvestorPlace
Novavax's COVID-19 Vaccine Approved In Switzerland
Via Benzinga
If You Invested $100 In Novavax 5 Years Ago, Here's How Much You Would Have Today
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 13.94% on an annualized basis producing an average annual return of 27.26%. Currently, Novavax has a market capitalization of... 
Via Benzinga
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ: NVAX) shares are trading lower Tuesday. The stock fell to new 52-week lows early in the session, but has since recovered. Novavax on Tuesday... 
Via Benzinga
UK-Based Start-Up Working On Next COVID-19 Vaccine Using Animal Feces: FT
Via Benzinga
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
Via Benzinga
What Volatility in Novavax Means for Investors
Novavax continues to await FDA news about its Covid-19 vaccine, but that's not everything that drives the price of NVAX stock. 
Via InvestorPlace
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ
In the latest phase of the COVID-19 pandemic, federal and local officials are leaving it up to people to assess if they need booster shots, whether to wear a mask and how long to isolate after a... 
Via Benzinga
The Longer the Wait, The Smaller the Opportunity for Novavax
The delay in FDA approval is making the opportunity smaller for Novavax, but the opportunity still remains. NVAX stock is a hold. 
Via InvestorPlace
Novavax: The Party’s Over
Novavax was a great speculation on hopes for its Covid-19 vaccine, but now that the virus is becoming endemic, sentiment is waning. 
Via InvestorPlace
Will Novavax Stock Continue to Trend Lower?
NVAX stock is likely to remain depressed as the market for Covid-19 vaccine shrinks. Its combination vaccines could be a positive catalyst. 
Via InvestorPlace
Novavax And Its Plan To Target The Vaccine Resistant Notch Another Win
Swiss officials authorized the company's Covid vaccine for conditional use. 
Via Investor's Business Daily
Novavax Stock Up on Swiss Approval of Nuvaxovid
Novavax’s Covid-19 vaccine Nuvaxovid just got approved for in Switzerland. NVAX stock is up on news. It couldn’t have come at a better time. 
Via InvestorPlace
Novavax Stock Is Slumping: Why Buy the Dip?
Novavax lost nearly one-fifth of its value in the last week and risks further selling pressure, despite offering an mRNA alternative. 
Via InvestorPlace
Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization
NVAX stock isn't a darling on Wall Street right now, but a rally could be just around the corner as Novavax pursues its global ambitions. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Vaccine Makers Down on FDA Meeting, Novavax Most at Risk
The major covid-19 vaccine makers are all down, anticipating bad-for-business news from the FDA. However, NVAX stock has the most to lose. 
Via InvestorPlace
Dear Biotech Investors: Novavax’s Comparable Vaccine Matters
Researchers compared Novavax’s vaccine to three others on the market, offering a thorough glimpse of protection from boosters. 
Via InvestorPlace
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.